Figures & data
Figure 1 Extent to which pain has interfered with daily life over the past 4 weeks.
Abbreviations: HERO, Hemophilia Experiences, Results and Opportunities; w/o, without.
![Figure 1 Extent to which pain has interfered with daily life over the past 4 weeks.](/cms/asset/9e43cdca-0bf0-4fc7-a316-70cdf99c7396/dppa_a_87659_f0001_c.jpg)
Table 1 EQ-5D index by hemophilia type and treatment regimen for adult global and US HERO populations
Table 2 EQ-5D index by country
Table 3 EQ-5D index by age group
Figure 2 “VAS health” score for patients with and without inhibitors.
Abbreviations: HERO, Hemophilia Experiences, Results and Opportunities; PWH, persons with hemophilia; VAS, visual analog scale.
![Figure 2 “VAS health” score for patients with and without inhibitors.](/cms/asset/6ea90339-53ee-4843-8a85-9b494ea6b499/dppa_a_87659_f0002_b.jpg)
Figure 3 Employment and bleed frequency by EQ-5D, pain interference, and self-reported arthritis.
Abbreviations: HERO, Hemophilia Experiences, Results and Opportunities; PWH, patients with hemophilia.
![Figure 3 Employment and bleed frequency by EQ-5D, pain interference, and self-reported arthritis.](/cms/asset/1c0f785d-0170-4b24-bfdd-518794a68682/dppa_a_87659_f0003_c.jpg)
Figure 4 HCP utilization by EQ-5D, pain interference, and self-reported arthritis.
Abbreviations: HCP, health care practitioner; HERO, Hemophilia Experiences, Results and Opportunities; PWH, patients with hemophilia.
![Figure 4 HCP utilization by EQ-5D, pain interference, and self-reported arthritis.](/cms/asset/57e666cb-c964-44a2-befb-dff48cffcf9e/dppa_a_87659_f0004_c.jpg)
Table S1 Demographics of the eight-country post hoc analysis patient population